This is trading around $10 as i speak. I understand that the by making a public offering has mad some investors a little angry but has undoubtedly created opportunity for new investors to join in. they have made a Preliminary Q2 announcement: 58% increase in revenue from Q2 2019. The list of accomplishment for Q2 is very good.
Hello,
What is CTSO?
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology.
News
My Thoughts For You
I see a bearish divergence on the daily...
Summary
Target $30, Stop $5. (Analyst price-targets around $14-$17).
COVID-19 put spotlight on their flagship product Cytosorb, as it gained emergency FDA approval for treatment of severe COVID-19 patients.
As further approvals for removal of ticagrelor and rivaroxaban have followed, Cytosorb can potentially become the "standard of care" alongside blood...
MONMOUTH JUNCTION, N.J., March 25, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, provided an update from its Chief Executive Officer, Dr. Phillip Chan, MD,...
CTSO is set to report earnings early next week,
given that this was a requested chart, I have not had time to dig in to the company's fundamental financials and create a good estimate of what to expect from its earnings.
GIVEN THE TECHNICAL ANALYSIS ALONE:
WE are currently hovering a buy zone, and have broken in to it once. At its current level, we are ready to...
bottom of cloud 5.50-5.70/enter with a confirmation positive candle/strong group/diversify/cci and percent r upper range/money flow excellent/adx beginning like 10 to 40/pvt good/relative strength strong/stop loss 8 ema/
